Oblique Therapeutics’ SEK 53.2 Million Rights Offering

MAQS advised Oblique Therapeutics on the deal.Oblique Therapeutics AB (publ) completed a rights issue of approximately SEK 53.2 million. Oblique Therapeutics is a privately held Swedish…

This content is for Standard 1 Year members only.
Login Join Now
Federica Tiefenthaler

Author: Federica Tiefenthaler

This content is for Standard 1 Year members only.
Login Join Now